74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Cytokinetics Inc
Closed
SectorHealthcare
64.03 7.9
Overview
Share price change
24h
Min
59.22
Max
64.21
Income | 123M -183M |
|---|---|
Sales | 16M 18M |
Profit margin | -1,030.87 |
Employees | 673 |
EBITDA | 97M -180M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +56.88% upside |
Next Earnings | 5 May 2026 |
|---|
Market Cap | -693M 7.7B |
|---|---|
Previous open | 56.13 |
Previous close | 64.03 |
News Sentiment
By Acuity
50%
50%
201 / 348 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Cytokinetics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Cytokinetics Inc Forecast
Price Target
By TipRanks
56.88% upside
12 Months Forecast
Average 93.47 USD 56.88%
High 136 USD
Low 67 USD
Based on 17 Wall Street analysts offering 12 month price targets forCytokinetics Inc - Dist in the last 3 months.
Sentiment
By Acuity
201 / 348 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Cytokinetics Inc
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Live chat